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Background/aim: The prevalence of Helicobacter pylori is reported to be roughly 80% in Turkey, and only very few culture-based studies
are available on antibacterial resistance in adult dyspeptic patients. This study was carried out in adult dyspeptic patients with an aim to:
(i) detect H. pylori by invasive tests (culture, polymerase chain reaction, and histopathology) and (ii) determine the current resistance
rates of H. pylori isolates to six antibiotics, including rifampicin.
Materials and methods: This study was conducted in 422 adult dyspeptic patients. The presence of H. pylori was demonstrated by
culture, polymerase chain reaction, and the histopathology of gastric biopsy material. Antibacterial susceptibility was determined with
the E-test.
Results: The mean age of the patients was 50 ± 15 (range 18–90), and 265 (63%) of them were female. By culture, polymerase chain
reaction, and histopathology, the presence of H. pylori was detected at rates of 35% (148/422), 67% (281/422), and 53% (224/422),
respectively. The prevalence of H. pylori was determined as 75.6% (319/422). Metronidazole, levofloxacin, clarithromycin, and rifampicin
resistance rates were 62%, 36%, 19%, and 12%, respectively. Monodrug, dual-drug, and multidrug resistance rates were ascertained as
36.9%, 29.4%, and 10.5%, respectively. All of the isolates were susceptible to amoxicillin and tetracycline.
Conclusion: This study revealed the current prevalence of H. pylori in adult dyspeptic patients as 75.6%, and thereby, showed that
infection with this pathogen remains highly prevalent. Although resistance to metronidazole and levofloxacin has increased over time,
clarithromycin resistance rate has decreased. The high levels of resistance to metronidazole and levofloxacin limit the empirical use of
these antibiotics in the eradication protocol. Owing to the low level of resistance determined for rifampicin, this antibiotic could be
included in the eradication protocol, in the event of the need for rescue therapy in Turkey.
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1. Introduction
Helicobacter pylori is a gram-negative microaerophilic
bacterium acquired orally during childhood, and is
known to colonize the gastric mucosa [1,2]. Being
estimated to have colonized almost half of the world
population, this pathogen may cause gastritis, peptic
ulcer, gastric malignancies, immune thrombocytopenic
purpura, iron deficiency anaemia, and vitamin B12
deficiency. Thus, H.pyloriis considered a major public
health concern [3–6]. The Maastricht IV and V/Florence
Consensus Reports suggest that, to succeed in managing
the diseases mentioned above, the presence of H. pyloris
hould be investigated and eradication treatment should be

instituted [4,6]. Furthermore, the Kyoto Global Consensus
Report highlights that H. pylori eradication could prevent
the aforementioned diseases, and also describes gastric
colonisation with this bacterium as an infectious disease,
irrespective of the clinical signs and symptoms observed
[7].
H. pylori can be detected by several invasive methods,
including culture, polymerase chain reaction (PCR), the
rapid urease test, and histopathological examination, or by
noninvasive methods such as the H. pyloris tool antigen
test, urea breath test (UBT), and serological tests [8–11].
To date, a global standard treatment protocol has
not been established for H. pylori. Therefore, treatment
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is based on the combined administration of empirically
selected two or three antibiotics and the use of high doses
of proton-pump inhibitors (PPIs). However, the success
rate of this empirical treatment remains unsatisfactory due
to increased levels of multidrug resistance [12].
As resistance to the antibiotics used for the eradication
of H. pylori is increasing at a global level and eventually
hinders treatment, it is suggested that the up-to-date
susceptibility status of these antibiotics be determined
by culture and an eradication programme be developed
accordingly in each country [13].
In Bursa province, where the present study was
conducted, the preceding investigation of the antibiotic
resistance of H. pylori isolates was performed 12 years ago
[14]. To the authors’ knowledge, there is no investigation
on the antibiotic resistance status of H. pylori in Bursa,
other than the mentioned study [14]. In addition, there is
no study on rifampicin (RD) resistance in H. pylori isolates
from Turkey.
This study was carried out in adult dyspeptic patients
with an aim to: (i) detect H. pylori by invasive tests (culture,
polymerase chain reaction, and histopathology), and (ii)
determine the current resistance rates of H. pylori isolates
to six antibiotics, including rifampicin.
2. Material and methods
2.1. Patients
In total 422 adult dyspeptic patients were enrolled in this
cross-sectional study. These patients underwent upper
gastrointestinal (GI) endoscopy under sedation at the
Department of Gastroenterology, Bursa Yüksek İhtisas
Training and Research Hospital, University of Health
Sciences, Turkey, from March 2018 to September 2019. The
adult patients included in this study were aged 18 and over,
presented with dyspeptic symptoms (postprandial fullness,
early satiation, epigastric pain, and epigastric burning) and
were referred for upper GI endoscopy. Patients, known to
be pregnant or diagnosed with coagulation disorders and
to have received prior eradication treatment for H. pylori or
undergone gastric surgery, were excluded from the study.
Patients with a medical history of antibiotic use in the last
6 weeks were also excluded. Demographic and endoscopic
data were recorded for all patients. All participants
provided written informed consent before participating in
the study. This study was approved by the Local Research
Ethics Committee of Erciyes University Medical Faculty
and designed in accordance with the 2013 Brazil version of
the Helsinki Declaration. The Ethics Committee reference
number is 2018/135.
2.2. Gastric biopsy specimens
The upper GI endoscopy procedure involved the collection
of four gastric biopsy specimens from each patient,
including two from the antrum and two from the corpus.
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Two of the specimens (1 antrum, 1 corpus) were transferred
into 10% formalin solution and used for histopathological
examination. The other two specimens were transferred
into sterile Eppendorf tubes, containing 500 µL of brain
heart infusion (BHI) broth (CM1135B, Thermo Fisher
Scientific, Waltham, MA, USA), for bacteriological and
molecular analyses. Histopathological examination was
performed at the Department of Pathology, Bursa Yüksek
İhtisas Training and Research Hospital, University of
Health Sciences. Bacteriological and molecular analyses
were conducted at the Department of Microbiology,
Faculty of Veterinary Medicine, Erciyes University.
2.3. Histopathological examination
The biopsyspecimens were fixed in 10% formalin solution
and embedded in paraffin. The sections cut from the
paraffin blocks were stained with haematoxylin and eosin
(H&E) and examined by an experienced pathologist [15].
2.4. Culture
The biopsy specimens maintained in BHI broth (CM1135B,
Thermo Fisher Scientific) were ground using a sterile glass
rod and homogenized. Twenty microliters of this material
was inoculated onto Columbia blood agar base (CM0331B,
Thermo Fisher Scientific) enriched with 10% defibrinated
horse blood and Dent supplement (SR0147E, Thermo
Fisher Scientific). The inoculated plates were incubated at
37 °C in a microaerobic atmosphere (Anaerocult C, Merck
Millipore, Darmstadt, Germany) for 7–10 days. At the end
of the incubation period, the H. pylori-suspect colonies (S
type, gram-negative, and oxidase-, catalase-, and ureasepositive) were assessed and their pure cultures were
prepared [16,17]. The pure cultures of the isolates were
stored in BHI broth supplemented with 15% glycerol at –84
°C for further use in molecular analyses and antibacterial
susceptibility tests.
2.5. Molecular analysis
a) DNA extraction
Commercial microbial DNA isolation kits were used to
extract DNA from both the biopsy samples (Roche high
pure PCR Template Preparation Kit, Mannheim, Germany)
and the H. pylori isolates obtained from culture (DNeasy
UltraClean Microbial Kit, Qiagen, Hilden, Germany). The
extraction procedures were performed in accordance with
the manufacturer’s instructions.
b) Polymerase chain reaction (PCR)
The PCR method was used to demonstrate the presence of
H. pylori in the gastric biopsy specimens and to confirm the
identification of the isolates recovered from the selective agar
as H. pylori by phenotypic tests. For this purpose, primers
(glmM-F 5’-AAGCTTTTAGGGGTGTTAGGGGTTT-3’
and glmM-R 5’-AAGCTTACTTTCTAACACTAAC GC3’) specific to the phosphoglucosamine mutase (glmM)
gene of H. pylori were used, and the test was performed
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by a method of Lu et al. [18]. The amplification cycles
consisted of denaturation at 93 °C for 1 min, primer
annealing at 58 °C for 1 min, and extension at 72 °C for 1
min. Samples were amplified through 35 cycles. Amplified
products were resolved by gel electrophoresis on 1.5%
agarose (Biomax, Agarose, Lot no. 124543PR, from Prona,
European Economic Community) and visualized under
a UV transilluminator (G:BOX Chemi XRQ; Syngene,
Cambridge, UK). Bands, which were 294-bp in size, were
considered as a positive result.
2.6. Antibacterial susceptibility testing
The minimal inhibitory concentration (MIC) values of
amoxicillin, clarithromycin, levofloxacin, metronidazole,
rifampicin, and tetracycline against the H. pylori isolates
were determined with the E-test. Mueller–Hinton agar
supplemented with 7% defibrinated horse blood (R54092,
Thermo Fisher Scientific) was used for this purpose.
Accordingly, a suspension prepared from 3-day-old
H. pylori cultures (Mac Farland No:3) was spread onto
Mueller–Hinton agar (CM0337B, Thermo Fisher Scientific)
supplemented with 7% defibrinated horse blood, and after
the agar surface dried, the E-test (The Liofilchem MIC
Test Strips, Italy) strips of the selected antibiotics were
placed onto the agar. The plates were incubated at 37 °C in
a microaerobic environment for 48–72 h [16]. The results
were evaluated according to the criteria of the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) [19]. The MIC values (mg/L) of amoxicillin,
clarithromycin, tetracycline, metronidazole, levofloxacin,
and rifampicin were≤0.125, ≤0.5, ≤1, ≤8, ≤1, and ≤1,
respectively. Isolates, which were resistant to three or more
antibiotics, were considered to be multidrug resistant.
2.7. Standard strain
Helicobacter pylori ATCC 700824 was used as a positive
control in culture, molecular analysis, and antibiotic
susceptibility tests.
2.8. Criterion used to detect the presence of H. pylori
H. pylori was considered to be present in the samples,
when the result of any of the invasive tests (culture, PCR,
and histopathology) was positive.
2.9. Statistical analysis
Data were analysed using the SPSSversion 20.0 (IBM
Corporation, Armonk, NY, USA). Values were expressed
as mean ± standard deviation for normally distributed
variables, and as count and percent for categorical
variables.
3. Results
3.1. Clinical data
In total, 422 adult dyspeptic patients were included in this
study. The mean age of the patients was 50 ± 15 years (range:
18–90) and 265 (63%) of them were female. The most

common endoscopic finding was gastritis, accounting for
62%, followed by reflux esophagitis (16%), duodenal ulcer/
duodenitis (15%), benign gastric ulcer (4.5%), normal
gastric mucosa (2%), and gastric malignancy (0.5%)
(Table 1). Gastritis, benign gastric ulcer, normal gastric
mucosa, and gastric malignancy were also demonstrated
histopathologically.
3.2. Prevalence of H. pylori and results of the invasive
tests
The prevalence of H. pylori was determined as 75.6%
(319/422). The presence of H. pylori was detected at rates
of 35% (148/422), 67% (281/422), and 53% (224/422)
by culture, PCR, and histopathological examination,
respectively (Figure 1). A representative image of the
agarose gel electrophoresis of the PCR products is shown
in Figure 2.
3.3. Antibacterial susceptibility testing
Out of the 148 H. pylori isolates recovered from culture, 15
could not be subcultured with passages. Thus, 133 isolates
were tested for antibacterial susceptibility. Based on the
test results, all 133 (100%) isolates were susceptible to
amoxicillin and tetracycline. Metronidazole, levofloxacin,
clarithromycin, and rifampicin resistance were determined
at levels of 62%, 36%, 19%, and 12%, respectively (Figure
1). A representative image of the E-test is shown in Figure
3. A detailed assessment of the test results demonstrated
that, out of the 133 isolates, 31 (23.3%) were susceptible
to all of the antibiotics tested, 49 (36.9%) were resistant
to a single antibiotic, 39 (29.4%) were resistant to two
antibiotics, and 14 (10.5%) were multidrug resistant (Table
2).

Table 1. Demographic and clinical data of the patients (n: 422).
Characteristics

n (%)

Age (mean ± SD)

50 ± 15

Sex
Male

157 (37)

Female

265 (63)

Endoscopic findings
Gastritis

261 (62)

Reflux esophagitis

68 (16)

Duodenal ulcer/duodenitis

62 (15)

Gastriculcer

19 (4.5)

Normal

10 (2)

Gastric malignancy

2 (0.5)

SD: Standard deviation.
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422 adult dyspeptic patients

2 biopsies for histopathology

2 biopsies for culture and PCR

H.pylori positivity by

Culture: 35% (148/422 )

PCR: 67% (281/422)

Histopathology : 53% (224/422)

Prevale nce of H.pylori: 75.6 % (319/422)

Antibiogram (n: 133 isolates)

Antibiotic resistance rates
(%)

.
.
.
.
.
.

MTZ: 62
LE: 36
CLR: 19
RD: 12
AML: 0
TE:
0

AML: Amoxicillin, TE: Tetracycline, MTZ: Metronidazole, LE: Levofloxacin, CLR:
Clarithromycin, RD: Rifampicin, PCR: Polymerase Chain Reaction
Figure 1. Flow diagram of the current study.
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Figure 2. Agarose gel electrophoresis of PCR products obtained by using primer pairs glmM-F and glmM-R (297bp). NC:
Negative control (distilled water), PC: Positive control (H. pylori, ATCC 700824), Representative positive samples (9, 66, 75,
77, 99, 106, 112, 160, 205, 268): H. pylori isolates recovered from gastric biopsies in the current study M: Marker, 100bp DNA
Ladder H3 RTU, GeneDireX.

4. Discussion
To the authors’ knowledge, the present study is the most
comprehensive molecular and culture-based research
conducted to date on H.pylori in Turkey. Furthermore, this
study is the first to report rifampicin resistance in H.pylori
isolates from Turkey.
The prevalence of H. pylori varies greatly in developed
and developing countries (18.9–87.7%) [20]. In a
community-based survey conducted in 4663 adults in
Turkey, the prevalence of H. pylori was determined as
82.5% with the UBT [21]. The prevalence of H. pylori in
dyspeptic patients is reported to range between 17% and
34% in developed countries [22,23], 75.6% and 86% in
developing countries [24,25], and 59.6% and 71.3% in
Turkey [26,27]. In the present study, the prevalence of H.
pylori (75.6%) was higher than the prevalence reported
for developed countries and similar to that reported for
developing countries.
As is the case throughout the world, in Turkey, the
antibiotics most commonly used for the eradication of
H. pylori are clarithromycin, metronidazole, levofloxacin,
tetracycline, and amoxicillin [28–31]. Rifampicin is
generally used for the treatment of tuberculosis, therefore,
in order to prevent the development of resistance, this
antibiotic is purposefully not used for the empirical
treatment of H. pylori in Turkey.

Reports have shown that the resistance of H. pylori
to these six antibiotics varies among both countries and
regions [12,13,32–35]. In most of the WHO regions,
clarithromycin, metronidazole, and levofloxacin resistance
rates of >15% have been reported [13,36]. Furthermore,
tetracycline and amoxicillin resistance rates have been
reported to be <10% across the globe [36,37]. It has also
been reported that, rifampicin resistance ranges between
0% and 33% [16,36,38–40]. In addition, clarithromycin,
metronidazole, levofloxacin, tetracycline, and amoxicillin
resistance rates range between 18% and 34%, 28.7%
and 56%, 0% and 22%, 0% and 10%, and 0% and 14%,
respectively, in different regions of the world [13,16,39–
41], and are 3.6% and 28.1%, 33.8% and 64.9%, 8% and
21.9%, 16.1%, and 20.7%, respectively, in the neighbouring
countries of Turkey [38,40,42,43].
According to research conducted in different regions of
Turkey in the past decade, clarithromycin, metronidazole,
levofloxacin, tetracycline, and amoxicillin resistance rates
range between 18.1% and 38.1%, 31.1% and 45.5%, 18.2%
and 34%, 0% and 9.1%, and 0% and 2.9%, respectively
[27,44–46]. In a previous study carried out in Bursa
province, which is also the location of the present study,
the rates of clarithromycin, metronidazole, tetracycline,
and amoxicillin resistance were found to be 41.9%, 41.9%,
3.2%, and 3.2%, respectively [14] (Table 3).
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Figure 3. Representative images regarding E-test rifampicin, clarithromycin, levofloxacin, and metronidazole.

The present study demonstrated that clarithromycin
resistance (19%) had decreased over time in Turkey, and
this was attributed to the clinical use of clarithromycin
having decreased. On the other hand, metronidazole
(62%) and levofloxacin (36%) resistance were ascertained
to have increased in Turkey. This could be attributed to the
increased clinical use of this antibiotic as well as to patients
not adhering to the prescribed administration dose
and period. In view of the high levels of clarithromycin,
metronidazole, and levofloxacin resistance detected
in Turkey, it is suggested that the empirical use of these
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antibiotics for the eradication of H. pylori should be
avoided, and their clinical use should be based on
antibacterial susceptibility test results. In addition, we
determined that all of the tested H. pylori isolates were
susceptible to tetracycline and amoxicillin. Therefore, it
is considered that both tetracycline and amoxicillin can
be safely used for the empirical treatment of H. pylori in
Turkey. To the authors’ knowledge, rifampicin resistance
has not been investigated before in H. pylori isolates from
Turkey. The present study reports, for the first time, the
resistance level of H. pylori to rifampicin as 12%. The level
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Table 2. Antibiotic susceptibility profiles of the H. pylori isolates
(n: 133).
Profiles

n (%)

No resistance to all drugs

31 (23.3)

Monodrug resistance

49 (36.9)

MTZ
LE
CLR
RD

37 (27.8)
9 (6.8)
1 (0.8)
2 (1.5)

Dual-drugs resistance
MTZ+LE
MTZ+CLR
MTZ+RD
LE+CLR
LE+RD
Multidrugs resistance

39 (29.4)
21 (15.8)
6 (4.5)
6 (4.5)
5 (3.8)
1 (0.8)
14 (10.5)

Triple resistance

12 (9.1)

MTZ+LE+CLR
MTZ+LE+RD
MTZ+CLR+RD
LE+CLR+RD

7 (5.3)
1 (0.8)
2 (1.5)
2 (1.5)

Quadruple resistance

2 (1.5)

MTZ+LE+CLR+RD

2 (1.5)

MTZ: Metronidazole, LE: Levofloxacin, CLR: Clarithromycin,
RD: Rifampicin.

Table 3. H. pylori antibiotic resistance rates among adults in recent years in different regions of Turkey.
Study year

Method

Number of
patients

Number of
isolates

Region(city)

2008

E-test

31

31

2010

E-test

149

2011

E-test

2013

E-test

2017

E-test

This study

E-test

Resistance rate (%)

Ref.

AML

TE

MTZ

CLR

LE

RD

West (Bursa)

3.2

3.2

41.9

41.9

-

-

14

102

South (Mersin)

0

9.1

45.5

18.1

18.2

-

46

344

104

North (Trabzon)

2.9

1

31.1

28.2

34

-

27

98

98

West (İstanbul)

0

0

35.5

36.7

29.5

-

44

63

63

West (İstanbul)

-

-

-

38.1

-

-

45

422

133

West (Bursa)

0

0

62

19

36

12

-

AML: Amoxicillin, TE: Tetracycline, MTZ: Metronidazole, LE: Levofloxacin, CLR: Clarithromycin, RD: Rifampicin, Ref.: Reference.

of resistance to rifampicin is lower than the resistance
levels to the antibiotics used for the eradication of H. pylori
in Turkey, including clarithromycin, metronidazole, and
levofloxacin. This result suggests that, rifampicin could
be included in the eradication protocol of H. pylori, when
salvage therapy is needed in Turkey.

Worldwide, the multidrug resistance rate of H. pylori
is reported as 9.6% [37]. In the present study, the rate
of resistance to at least one antibiotic was ascertained
as 76.6% and multidrug resistance was determined at a
rate of 10.5% (Table 2). Therefore, to achieve success in
the eradication of H. pylori, it is required to determine
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the current antibiotic resistance status, and to establish
appropriate eradication protocols in view of this status.
4.1. Limitations of the study
i-) The current study is monocentric, so the results
obtained may not accurately represent the entire territory
of Turkey.
ii-) This study does not include a sufficient number of
patients to determine the exact prevalence of H. pylori in
adult dyspeptic patients.

levels of resistance detected in H. pylori isolates to
metronidazole and levofloxacin would constitute a major
problem in empirical treatment. On the other hand, as no
resistance was detected to amoxicillin and tetracycline,
these antibiotics were considered to be safe for use in the
eradication of H. pylori. Furthermore, in view of the low
level of resistance to rifampicin, this antibiotic could be
included in the eradication protocol of H. pylori in Turkey
as an option for rescue therapy.

4. Conclusion
The prevalence of H. pylori in adult dyspeptic patients
was found to be higher than that in developed countries
and similar to that in developing countries. Resistance
to metronidazole and levofloxacin was determined
to have increased over time. Although resistance to
clarithromycin had decreased over time, it was observed
to remain above 15%. It is considered that the high
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